Search

The funds are from a competitive call through the 2021 State Programme to Promote Scientific-Technical Research and its Transfer (formerly known as Retos Colaboración).

The Andorran biotech company is working to obtain Good Manufacturing Practices (GMP) during the first half of 2023

Jordi Xiol has been promoted to Partner after joining Ysios Capital in 2019 Ysios is also incorporating Sanifit co-founder and CEO Joan Perelló as Venture Partner

BCN HEALTH has published 10 studies in 2022 assessing the incidence and cost of illness of different diseases in Spain.

The Galician Innovation Agency has awarded DIVERSA through the InnovaPeme program to implement its innovation plan in 2022 and 2023

Mikrobiomik aims to be the first company in the world to commercialize the first biologic medicine based on intestinal microbiota, in primary or recurrent Clostridiodes difficile infection

Laminar Pharmaceuticals S.A., se complace en anunciar el reclutamiento de los primeros 45 pacientes en el estudio clínico de fase II/III en glioblastoma de nuevo diagnóstico

 Trial will assess the safety and efficacy of iadademstat in pulmonary and extrapulmonary NECs

NIMBLE Diagnostics, ha cerrado con éxito una ronda de financiación donde han conseguido más un millón de euros liderada por Grow Ventures junto con Namarel Ventures e Inveniam Group

Barcelona, the leader in the biotechnology and life sciences sector in Spain, will host this edition from 26 to 28 September, which is the 20th anniversary of the event.

The spin-off of IRB Barcelona, the UB and SJD has a patented technology based on peptides (small proteins) that efficiently cross biological barriers, such as the blood-brain barrier that protects the

One of the key challenges in the process of developing new bioproducts is to overcome the transition period in which a technology under development is envisaged as promising

BCN HEALTH ha publicado el estudio Hospital Incidence and Medical Costs of Female Breast Cancer in Spain: A Retrospective Multicenter Study ' en la revista 'Current Cancer Therapy Reviews'

The science and technology company Merck has awarded the Merck Chair Award to the best works of the Master's Degree in Management of Biotechnology Companies in Health

R&D is at the heart of Almirall's strategy

6º Sachs Annual Neuroscience Innovation Forum 12º Annual LifeSci Advisors Corporate Access Event 41º Annual J.P. Morgan Healthcare Conference Invest Securities Biomed Forum 2023

The project has been approved in the call for public-private collaboration projects of the Ministry of Science and Innovation, with 3.3 million euros in funding from the Recovery, Transformation and

Corify Care and GENESIS Biomed will develop a technology platform that uses non-invasive mapping, mathematical models of the heart and artificial intelligence to predict the side effects of treatments

This is the first year that the company appears in the ranking established by CEPYME

Project will assess the efficacy of iadademstat in combination with checkpoint inhibitors and/or oncological vaccines

Since it was established in May 2017, the company has worked on more than 253 consultancy projects, mobilised over €67.5 million, and managed 19 rounds of funding for clients, including two in 2022